GBM Agile Trial

Brief description of study

The purpose of the research study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatments improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called “study drugs” and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. If you choose to participate in the study, you will be randomized like the flipping of a coin or the rolling of dice, to determine which treatment you will receive.

Clinical Study Identifier: s19-00633 Identifier: NCT03970447

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.